ArticleScientific reports2025
Ultrasound radiomics and deep learning for predicting antral follicle count and anti-Müllerian hormone.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
To overcome inter-observer variability in conventional antral follicle count (AFC) assessment and AMH testing limitations, we developed an AI-powered framework using routine 2D ultrasound to standardize ovarian-reserve evaluation in assisted reproductive technology (ART). This multicenter retrospective study analyzed 395 women with infertility from two affiliated hospitals. The cohort was divided into training (n = 210), internal-test (n = 91), and external-test (n = 94) cohorts. We established three prediction models: radiomics model, 674 IBSI-compliant features; deep-learning model, ResNet50-based feature extraction; fusion model, hybrid approach combining both modalities. Model performance was validated against the manual AFC and serum AMH levels. Sequential classification categorized patients into low, moderate, or high ovarian-response risk groups. Strong correlation and consistency existed between routine 2D ultrasound image AFCs and three-dimensional dynamic-scan AFCs. The deep learning-radiomics fusion model displayed superior AFC prediction (R²=0.743 internal/0.583 external), surpassing the performance of single-modality models (radiomics: 0.586/0.572; deep learning: 0.737/0.541). For AMH prediction, the fusion model maintained generalizability (external R²=0.509 vs. 0.420 radiomics and 0.352 deep learning, p < 0.05). In ovarian-response stratification, the fusion model achieved an AUC of 0.881 (95%CI: 0.828-0.925), which was 8.0% higher than that of individual models, with 69.1% sensitivity and 84.6% specificity for identifying high-risk patients requiring stimulation-protocol modifications. The developed AI framework enables standardized ovarian-reserve evaluation using routine 2D ultrasound, effectively bridging imaging limitations by synergizing radiomics and deep learning. Meanwhile, the model achieves clinical applicability by enabling personalized ovarian-stimulation protocol optimization, demonstrating particular value in resource-limited clinical environments without requiring advanced imaging infrastructure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.